Bexarotene

Carcinoma, Non-small-cell Lung

Dartmouth-Hitchcock Medical CenterSmall moleculePhase 3Dormant

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 57/ 100
Competitive Position: 65/ 100

Competitive context

1206 Active assets in the Carcinoma, Non-small-cell Lung cohort.

Asset / Sponsor	Phase	Rating
Zorifertinib Alpha Biopharma (Jiangsu) Co., Ltd.	Phase 2/3	BBB
Necitumumab Jonsson Comprehensive Cancer Center	Phase 3	BBB
Glumetinib Shanghai JMT-Bio Inc.	Phase 3	BBB
Veliparib AbbVie	Phase 3	BBB
Onartuzumab Hoffmann-La Roche	Phase 3	BBB

View all 50 →

Same molecule, other indications

Bexarotene is also rated in:

primary cutaneous T-cell non-Hodgkin lymphomaDormant

BBB

Indicative ·

74 / 100

primary cutaneous anaplastic large cell lymphomaDormant

BB

Indicative ·

65 / 100

mycosis fungoidesDormant

B

Indicative ·

63 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.